Abstract Obesity adversely affects outcome in pediatric acute lymphocytic leukemia and acute myeloid leukemia (AML). We asked if obesity, measured by body mass index (BMI), affected outcome in 329 adult AML patients treated with high-dose cytarabine and idarubicin-containing regimens administered according to actual body weight. Age≥60, unfavorable karyotype, secondary AML, and positive smoking status had adverse impact on overall survival in a multivariate analysis, while BMI did not. We conclude that high BMI should not be a barrier to administer high-dose cytarabine-containing regimens for AML induction.
Introduction
The prevalence of obesity has increased substantially over the past few decades and has more than doubled in adults in the USA [1] . Furthermore, obesity is a known risk factor for adult hematological malignancies [2] . Chemotherapy dosages for obese patients are often empirically reduced on the basis of ideal body weight because of concerns about excessive toxicity; however, dose reductions may compromise treatment outcomes [3, 4] . There is a paucity of information on the influence of body mass index (BMI) on the toxicity of intensive chemotherapy in adult AML and on progression-free survival (PFS) and overall survival (OS) following intensive chemotherapy [5, 6] . We compared toxicity data and survival outcomes across three BMI groups [normal (NL), overweight (OW), and obese (OB)], in 329 adults with AML, treated with similar AML induction chemotherapy administered by actual weights, to find out if obesity is a prognostic factor in AML.
Patients and methods
We queried the leukemia database for patients treated with high-dose cytarabine and idarubicin-containing regimens at the Roswell Park Cancer Institute (RPCI) between June 1990 and December 2008. Three hundred twenty-nine AML (except acute promyelocytic leukemia) patients eligible for high-dose cytarabine and idarubicin-containing regimens were found. The following patient data were scored: age, gender, weight, height, karyotype, smoking history, disease presentation (de novo vs. secondary), time of relapse, and allogeneic transplant. Patients' heights and weights were recorded at the time of induction chemotherapy. BMI was calculated using the World Health Organization (WHO) classification definition [7] 
Statistical analyses
Response criteria were standard [8] . PFS was defined as time from diagnosis until time of relapse. OS was defined as time from diagnosis until time of last follow-up or death.
Univariate analyses
Descriptive statistics and chi-square tests were used to explore associations between body mass index (BMI) and other characteristics of interest. The log rank (Mantel-Cox) test within the Kaplan-Meier (KM) analysis was used to assess statistically significant differences in mean PFS and OS (in months) according to various participant characteristics. All analyses were stratified by participant BMI at diagnosis (NL, OW, and OB).
Pulmonary and cardiac toxicities, infection, and multiorgan failure toxicities were obtained from medical records and were categorized according to the common terminology criteria for adverse events version 3. Furthermore, patients were categorized as having no toxicity or at least mild toxicity in any of the preceding areas. Differences in toxicity levels were assessed using chi-square analysis. Table 1 . There were significantly less smokers among the NL BMI patients (P=0.023) and more males among the OW BMI patients (P=0.006). No other differences were noted.
As shown in Table 2 , there were significantly less (P= 0.014) pulmonary complications for OW patients compared to NL or OB patients with regards to grade one pulmonary toxicities. However, no other statistically significant differences were discovered in the other (cardiac and infectious) toxicities among the different BMI groups. Pairwise comparisons found statistically significant differences in reporting pulmonary complications for both NW patients and OB patients compared to OW patients (NL vs. OW: p=0.023; OW vs. OB: p=0.010, not shown). However, there were no statistically significant differences in pulmonary toxicity between NL and OB patients (p=0.782), and no differences were found for either cardiac complications or infection between BMI subgroups. Overall, day 30 mortality was 5.7% for NL, 6.7% for OW, and 7.7%% for OB patients and was not statistically different (p= 0.840). Similarly, no statistically significant differences in 60-day mortality were observed by BMI category (p=0.277).
There was no statistically significant difference in OS for NL (36.5 months), OW (49.5 months), or OB patients (41.0 months) (P=0.471) based on univariate KM analysis (Table 3) . Patients who received arsenic trioxide did not show difference in PFS or OS in Cox proportional model when compared to patients who did not receive arsenic trioxide. However, statistically significant differences in OS were observed for smoking status, age, karyotype, AML presentation, and treatment decade based on univariate analysis. Similarly, no significant differences in PFS were observed between BMI strata (Table 3) ; PFS for NL, OW, and OB were 37.6 vs. 51.9 vs. 55.4 months, respectively, (P=0.247) based on KM analysis. Additional analysis was (Table 4) .
Discussion
Obesity has been associated with an increased risk of developing adult AML, but no survival data have been systematically studied [1, [10] [11] [12] . Establishing an association between obesity and outcomes could have significant implications for AML management [13] . We observed no association between BMI and outcome in adults with AML. However, we did see a trend toward improved survival for OW young (18-39 year old) populations (P=0.07). This may represent the limitations of BMI as a predictive tool since many AML patients will likely be in the OW group [14] .
Specifically, BMI makes no distinction between muscles versus fat mass, and therefore, muscular individuals can be categorized in a higher BMI status. Other methods to assess obesity status are waist circumference [16] [17] [18] , neck circumference [19, 20] , and hip-to-waist ratio [21] . All have been used to predict outcome. For example, a 20% increase in the risk of colon cancer recurrence or mortality was observed for every 10 cm increase in waist circumference [18] . This may represent improved classification complimentary to the BMI that is in current use. Furthermore, sensitivity analyses using an age-and gender-weighted BMI classification tool based on NHANES-1 classifications were set forth by Must et al [15] but were not widely adopted.
Our results are in contrast to those observed in pediatric AML. Specifically, a retrospective pediatric study showed poor outcome in obese and underweight children treated on Children's Cancer Group-2961 (CCG-2961) [5] . Both 
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Normal Weight (n=57) Overweight (n=62) Obese (n=54) P=0.450 B Fig. 1 a Curves based on Kaplan-Meier analyses assessing differences in overall survival by BMI status at diagnosis, excluding respondents who underwent allogeneic transplantation. Normal weight: n=97 (n=14 censored); Overweight: n=105 (n=18 censored); Obese: n=93 (n=19 censored). The + sign reflects censored patients. b Curves based on Kaplan-Meier analyses assessing differences in progression free survival by BMI status at diagnosis, excluding respondents who underwent allogeneic transplantation. Normal weight: n=57 (n=11 censored); Overweight: n=62 (n=15 censored); Obese: n=54 (n=17 censored). The + sign reflects censored patients underweight and overweight children with AML had increased treatment toxicities and decreased OS. However, this study utilized a pediatric scale, overweight (>95th percentile) or underweight (<1.0 percentile), and not the BMI WHO classification, which may explain the discrepancy between our report and CCG-2961. Furthermore, obesity is related to incidence, complications, and prognosis in acute promyelocytic leukemia [10, [22] [23] [24] , regardless of age. The reason for these discrepancies is not clear. However, our results are similar to a large retrospective study in the transplant setting of AML patients [25] . In that study encompassing 4,215 patients, BMI was not an adverse prognostic indicator for outcome, regardless of donor source.
Cardiac and pulmonary complications in obese populations have been extensively studied, and obesity's negative impact was clearly documented in patients with non-malignant diseases [26, 27] . Infectious complications can be increased due to decreased mobility, and glucose intolerance due to obesity. In our study, there was a statistical difference in pulmonary complications between OW vs. OB and OW vs. NL populations. However, this difference did not appear to be a consistent finding throughout different grades of pulmonary toxicities in the different BMI categories. Of note, we detected a trend toward OS advantage in the young (18-39 years old) OW population, which may have been due to less pulmonary toxicity in this group.
We observed that patients diagnosed and treated in the 1990s had a significantly inferior OS compared to >2000s. When stratified by BMI status, OS was significantly longer in the NL and OB groups treated after 2000 but, interestingly, not in the OW group. We suspect that the survival benefits most likely represent improvements in supportive care and possibly allogeneic stem cell transplantation methods. This progressive chronologic survival improvement benefit was seen previously in a large AML population study in Sweden where all ages, except patients older than 80 years, had survival benefits with progressive chronologic time points [28] . A major caveat of this study is the sample size, compared to studies conducted in stem cell transplantation and pediatric AML. However, AML is a rare disease, and this sample size was sufficient to detect differences in other well-accepted AML prognostic factors such as age, WBC count, karyotype, etc., suggesting that if indeed BMI had a role, we should have been able to detect it. Another caveat of this study is its retrospective design and the need to collect data from physician notes within each patient's medical chart.
Interestingly, patients who were former smokers had worse survival outcomes compared to current smokers. A possible explanation for this phenomenon is that patients who quit smoking did so because of significant deterioration of their health prior to AML diagnosis such as pulmonary complications. One of the limitations of the smoking data is the lack of temporality in assessing time since smoking cessation as the current data only assessed smoking status at diagnosis. Therefore, it is possible that the "former smokers" continued smoking until just prior to diagnosis or current smokers quit just after diagnosis with AML. Although this limitation of our data is likely to result in misclassification, smoking status was not the main exposure of interest studied in this manuscript.
In summary, obesity has been shown to adversely affect outcome in pediatric AML [5] and acute promyelocytic leukemia [39] but not in adult AML patients, based on our results. Therefore, we conclude that BMI is not a poor prognostic factor in AML and high BMI should not be a barrier for intensive induction chemotherapy.
